A guide to the management of clozapine-related tolerability and safety concerns

Leslie Citrome, Joseph Patrick McEvoy, Stephen R. Saklad

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Clozapine is a highly effective antipsychotic medication, which provides a range of significant benefits for patients with schizophrenia, and is the standard of care for treatment-resistant schizophrenia as well as for reducing the risk of suicidal behaviors in schizophrenia and schizoaffective disorder. However, clozapine is widely underutilized, largely because prescribing clinicians lack experience in prescribing it and managing its adverse events (AEs). Clozapine is associated with three uncommon but immediately dangerous AEs - agranulocytosis, myocarditis/cardiomyopathy, and seizures - as well as AEs that may become dangerous if neglected, including weight gain, metabolic syndrome and constipation, and others that are annoying or distressing such as sedation, nighttime enuresis and hypersalivation. Because of the risk of agranulocytosis, clozapine formulations are available only through restricted distribution via a patient registry, with mandatory, systematized monitoring for absolute neutrophil count using a specific algorithm. We identified articles on managing clozapine-associated AEs by searching PubMed using appropriate key words and search techniques for each topic. A review of the prevalence and clinical characteristics of clozapine-associated AEs shows that these risks can be managed efficiently and effectively. The absolute risks for both agranulocytosis and myocarditis/cardiomyopathy are low, diminish after the first six months, and are further reduced with appropriate monitoring. Weight gain/metabolic disorders and constipation, which develop more gradually, can be mitigated with regular monitoring and timely interventions. Sedation, hypersalivation, and enuresis are common but manageable with ameliorative measures and/or medications.

Original languageEnglish (US)
Pages (from-to)163-177D
JournalClinical Schizophrenia and Related Psychoses
Volume10
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Clozapine
Safety
Agranulocytosis
Sialorrhea
Enuresis
Schizophrenia
Myocarditis
Constipation
Cardiomyopathies
Weight Gain
Standard of Care
Risk-Taking
PubMed
Psychotic Disorders
Antipsychotic Agents
Registries
Seizures
Neutrophils

Keywords

  • Adverse events
  • Clozapine
  • Guidelines
  • Management
  • Safety
  • Schizophrenia
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A guide to the management of clozapine-related tolerability and safety concerns. / Citrome, Leslie; McEvoy, Joseph Patrick; Saklad, Stephen R.

In: Clinical Schizophrenia and Related Psychoses, Vol. 10, No. 3, 01.09.2016, p. 163-177D.

Research output: Contribution to journalReview article

@article{a5db3068f1e447e7a7f547d7f2619f1f,
title = "A guide to the management of clozapine-related tolerability and safety concerns",
abstract = "Clozapine is a highly effective antipsychotic medication, which provides a range of significant benefits for patients with schizophrenia, and is the standard of care for treatment-resistant schizophrenia as well as for reducing the risk of suicidal behaviors in schizophrenia and schizoaffective disorder. However, clozapine is widely underutilized, largely because prescribing clinicians lack experience in prescribing it and managing its adverse events (AEs). Clozapine is associated with three uncommon but immediately dangerous AEs - agranulocytosis, myocarditis/cardiomyopathy, and seizures - as well as AEs that may become dangerous if neglected, including weight gain, metabolic syndrome and constipation, and others that are annoying or distressing such as sedation, nighttime enuresis and hypersalivation. Because of the risk of agranulocytosis, clozapine formulations are available only through restricted distribution via a patient registry, with mandatory, systematized monitoring for absolute neutrophil count using a specific algorithm. We identified articles on managing clozapine-associated AEs by searching PubMed using appropriate key words and search techniques for each topic. A review of the prevalence and clinical characteristics of clozapine-associated AEs shows that these risks can be managed efficiently and effectively. The absolute risks for both agranulocytosis and myocarditis/cardiomyopathy are low, diminish after the first six months, and are further reduced with appropriate monitoring. Weight gain/metabolic disorders and constipation, which develop more gradually, can be mitigated with regular monitoring and timely interventions. Sedation, hypersalivation, and enuresis are common but manageable with ameliorative measures and/or medications.",
keywords = "Adverse events, Clozapine, Guidelines, Management, Safety, Schizophrenia, Tolerability",
author = "Leslie Citrome and McEvoy, {Joseph Patrick} and Saklad, {Stephen R.}",
year = "2016",
month = "9",
day = "1",
doi = "10.3371/1935-1232.10.3.163",
language = "English (US)",
volume = "10",
pages = "163--177D",
journal = "Clinical Schizophrenia and Related Psychoses",
issn = "1935-1232",
publisher = "Walsh Medical Media, LLC",
number = "3",

}

TY - JOUR

T1 - A guide to the management of clozapine-related tolerability and safety concerns

AU - Citrome, Leslie

AU - McEvoy, Joseph Patrick

AU - Saklad, Stephen R.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Clozapine is a highly effective antipsychotic medication, which provides a range of significant benefits for patients with schizophrenia, and is the standard of care for treatment-resistant schizophrenia as well as for reducing the risk of suicidal behaviors in schizophrenia and schizoaffective disorder. However, clozapine is widely underutilized, largely because prescribing clinicians lack experience in prescribing it and managing its adverse events (AEs). Clozapine is associated with three uncommon but immediately dangerous AEs - agranulocytosis, myocarditis/cardiomyopathy, and seizures - as well as AEs that may become dangerous if neglected, including weight gain, metabolic syndrome and constipation, and others that are annoying or distressing such as sedation, nighttime enuresis and hypersalivation. Because of the risk of agranulocytosis, clozapine formulations are available only through restricted distribution via a patient registry, with mandatory, systematized monitoring for absolute neutrophil count using a specific algorithm. We identified articles on managing clozapine-associated AEs by searching PubMed using appropriate key words and search techniques for each topic. A review of the prevalence and clinical characteristics of clozapine-associated AEs shows that these risks can be managed efficiently and effectively. The absolute risks for both agranulocytosis and myocarditis/cardiomyopathy are low, diminish after the first six months, and are further reduced with appropriate monitoring. Weight gain/metabolic disorders and constipation, which develop more gradually, can be mitigated with regular monitoring and timely interventions. Sedation, hypersalivation, and enuresis are common but manageable with ameliorative measures and/or medications.

AB - Clozapine is a highly effective antipsychotic medication, which provides a range of significant benefits for patients with schizophrenia, and is the standard of care for treatment-resistant schizophrenia as well as for reducing the risk of suicidal behaviors in schizophrenia and schizoaffective disorder. However, clozapine is widely underutilized, largely because prescribing clinicians lack experience in prescribing it and managing its adverse events (AEs). Clozapine is associated with three uncommon but immediately dangerous AEs - agranulocytosis, myocarditis/cardiomyopathy, and seizures - as well as AEs that may become dangerous if neglected, including weight gain, metabolic syndrome and constipation, and others that are annoying or distressing such as sedation, nighttime enuresis and hypersalivation. Because of the risk of agranulocytosis, clozapine formulations are available only through restricted distribution via a patient registry, with mandatory, systematized monitoring for absolute neutrophil count using a specific algorithm. We identified articles on managing clozapine-associated AEs by searching PubMed using appropriate key words and search techniques for each topic. A review of the prevalence and clinical characteristics of clozapine-associated AEs shows that these risks can be managed efficiently and effectively. The absolute risks for both agranulocytosis and myocarditis/cardiomyopathy are low, diminish after the first six months, and are further reduced with appropriate monitoring. Weight gain/metabolic disorders and constipation, which develop more gradually, can be mitigated with regular monitoring and timely interventions. Sedation, hypersalivation, and enuresis are common but manageable with ameliorative measures and/or medications.

KW - Adverse events

KW - Clozapine

KW - Guidelines

KW - Management

KW - Safety

KW - Schizophrenia

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84994045569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994045569&partnerID=8YFLogxK

U2 - 10.3371/1935-1232.10.3.163

DO - 10.3371/1935-1232.10.3.163

M3 - Review article

C2 - 27732102

AN - SCOPUS:84994045569

VL - 10

SP - 163-177D

JO - Clinical Schizophrenia and Related Psychoses

JF - Clinical Schizophrenia and Related Psychoses

SN - 1935-1232

IS - 3

ER -